AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37525298 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with outpatient treatment
Number of subjects: 762
Study 37525354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP control (target of 110 to <130 mmHg)
Number of subjects: 8283
Study 37525369 — intervention group
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (2 × 1.5 mg/kg, postoperative days 0 and 1) and infliximab (5 mg/kg, postoperative day 2) followed by mycophenolate-free tacrolimus-based immunosuppression for 12 mo
Number of subjects: 67
Study 37525369 — intervention group
Group type: EXPERIMENTAL
Intervention: mycophenolate-free tacrolimus-based immunosuppression
Number of subjects: 67
Study 37525369 — intervention group
Group type: EXPERIMENTAL
Intervention: study cohort
Number of subjects: 67
Study 37525373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 266
Study 37525373 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 266
Study 37525373 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS)
Number of subjects: 266
Study 37525414 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted transversus abdominis plane block (L-TAPB)
Number of subjects: 112
Study 37525414 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane block (U-TAPB)
Number of subjects: 112
Study 37525559 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised concurrent exercise training program
Number of subjects: 86
Study 37525559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 37525592 — intervention group
Group type: EXPERIMENTAL
Intervention: IV edaravone (edaravone-first group)
Number of subjects: 0
Study 37525592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo-first group)
Number of subjects: 0
Study 37525914 — intervention group
Group type: EXPERIMENTAL
Intervention: GJA4 variants (homozygous G variant, n = 84; 73%)
Number of subjects: 115
Study 37525914 — intervention group
Group type: EXPERIMENTAL
Intervention: TGFβ1 variants
Number of subjects: 115
Study 37525914 — intervention group
Group type: EXPERIMENTAL
Intervention: GJA4 variants
Number of subjects: 115
Study 37525973 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical trigeminal neuralgia
Number of subjects: 55
Study 37525973 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic trigeminal neuralgia
Number of subjects: 55
Study 37525974 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor cold air (<10°C) exposure for 30 minutes
Number of subjects: 118
Study 37525974 — intervention group
Group type: COMPARATOR
Intervention: Indoor room temperature exposure for 30 minutes
Number of subjects: 118
Study 37526012 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 0
Study 37526012 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37526060 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg daridorexant
Number of subjects: 4
Study 37526060 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 4
Study 37526103 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Gastrectomy (TG)
Number of subjects: 186
Study 37526103 — intervention group
Group type: COMPARATOR
Intervention: Distal Gastrectomy (DG)
Number of subjects: 186
Study 37526117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision robotic assisted surgery (SIRAS)
Number of subjects: 7
Study 37526149 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg iv. every 3 weeks
Number of subjects: 600
Study 37526149 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (ICC)
Number of subjects: 600
Study 37526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 2670
Study 37526194 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycaemic control
Number of subjects: 2670
Study 37526237 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (various conditions)
Number of subjects: 51
Study 37526237 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 51
Study 37526261 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 3361
Study 37526261 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 3361
Study 37526261 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 3361
Study 37526355 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37526436 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple benzodiazepine receptor agonists
Number of subjects: 0
Study 37526548 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm using current and prior low-dose CT examination
Number of subjects: 4902
Study 37526548 — intervention group
Group type: COMPARATOR
Intervention: Validated DL algorithm that only processed a single CT examination
Number of subjects: 4902
Study 37526694 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 49
Study 37526748 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended complete mesocolic excision (e-CME)
Number of subjects: 79
Study 37526748 — intervention group
Group type: COMPARATOR
Intervention: Standard complete mesocolic excision (s-CME)
Number of subjects: 79
Study 37526748 — intervention group
Group type: EXPERIMENTAL
Intervention: High tie of the inferior mesenteric artery during sigmoidectomy
Number of subjects: 79
Study 37526748 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 79
Study 37526748 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 79
Study 37526748 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm
Number of subjects: 79
Study 37526752 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PECS block (PreM)
Number of subjects: 34
Study 37526752 — intervention group
Group type: COMPARATOR
Intervention: Postoperative PECS block (PostM)
Number of subjects: 34
Study 37526856 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose MF/IND/GLY
Number of subjects: 1930
Study 37526856 — intervention group
Group type: COMPARATOR
Intervention: High-dose ICS/LABA
Number of subjects: 1930
Study 37526883 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4%
Number of subjects: 20
Study 37526883 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 20
Study 37526883 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% and Lidocaine 2%
Number of subjects: 20
Study 37526908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0
Study 37526908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 37526908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 37526908 — intervention group
Group type: COMPARATOR
Intervention: Placebo or active comparators (semaglutide 1 mg, insulin degludec, insulin glargine)
Number of subjects: 0
Study 37526934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural-puncture epidural (DPE)
Number of subjects: 140
Study 37526934 — intervention group
Group type: COMPARATOR
Intervention: Standard epidural
Number of subjects: 140
Study 37526936 — intervention group
Group type: EXPERIMENTAL
Intervention: Orteronel 300 mg orally twice daily
Number of subjects: 1313
Study 37526936 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50 mg orally daily
Number of subjects: 1313
Study 37526937 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise intervention
Number of subjects: 134
Study 37526937 — intervention group
Group type: COMPARATOR
Intervention: Attention control (weekly health education telephone calls)
Number of subjects: 134
Study 37526959 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Management of Adolescent Pain (WebMAP)
Number of subjects: 34
Study 37527039 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/BA.5 breakthrough infection
Number of subjects: 0
Study 37527039 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell responses of mRNA-vaccinated individuals
Number of subjects: 0
Study 37527039 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell immunity
Number of subjects: 0
Study 37527424 — intervention group
Group type: EXPERIMENTAL
Intervention: Core warming intervention
Number of subjects: 19
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline employment
Number of subjects: 578
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic disorder other than schizophrenia
Number of subjects: 578
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of untreated psychosis
Number of subjects: 578
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 578
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom remission without antipsychotic medication
Number of subjects: 578
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery
Number of subjects: 578
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use during follow-up
Number of subjects: 578
Study 37527479 — intervention group
Group type: EXPERIMENTAL
Intervention: All chronic illnesses
Number of subjects: 578
Study 37527726 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cord blood mononucleated cells (CBMNCs) delivered via intracoronary infusion during Norwood procedure, 4 doses of 15 mL each, without prior cryopreservation.
Number of subjects: 13
Study 37527730 — intervention group
Group type: COMPARATOR
Intervention: Best Practices (BP)
Number of subjects: 198
Study 37527730 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practices plus Financial Incentives (BP + FI)
Number of subjects: 198
Study 37527730 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practices plus Financial Incentives and Nicotine Replacement Therapy (BP + FI + NRT)
Number of subjects: 198
Study 37527856 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical therapy (PT)
Number of subjects: 303
Study 37527856 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based exercise training (IBET)
Number of subjects: 303
Study 37527856 — intervention group
Group type: COMPARATOR
Intervention: Usual care/wait list control
Number of subjects: 303
Study 37527887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health app for self-reporting
Number of subjects: 200
Study 37527887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health app usability
Number of subjects: 200
Study 37527887 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive and multivariate statistics
Number of subjects: 200
Study 37527890 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported, WhatsApp-assisted lifestyle modification intervention delivered by a trained nutritionist for 1 year (3 days after baseline and then monthly).
Number of subjects: 50
Study 37527890 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported, WhatsApp-assisted lifestyle modification intervention.
Number of subjects: 50
Study 37527898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime use of antihypertensives
Number of subjects: 0
Study 37527898 — intervention group
Group type: COMPARATOR
Intervention: Morning use of antihypertensives
Number of subjects: 0
Study 37527897 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-delivered education followed by 12 months of motivational interviewing (MI)-based health coaching
Number of subjects: 350
Study 37527897 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 350
Study 37527906 — intervention group
Group type: EXPERIMENTAL
Intervention: CD30-directed CAR-T cells
Number of subjects: 28
Study 37528149 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncommon, putatively functional genetic variants in TRD cases
Number of subjects: 149
Study 37528149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-selected gene sets related to lithium response
Number of subjects: 149
Study 37528149 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous TRD studies genes
Number of subjects: 149
Study 37528149 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF248 and STK19
Number of subjects: 149
Study 37528149 — intervention group
Group type: EXPERIMENTAL
Intervention: PHYIN1 and PRKRA
Number of subjects: 149
Study 37528149 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC7A8
Number of subjects: 149
Study 37528149 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDHHC3
Number of subjects: 149
Study 37528259 — intervention group
Group type: EXPERIMENTAL
Intervention: Social jetlag (SJL) group
Number of subjects: 1002
Study 37528259 — intervention group
Group type: COMPARATOR
Intervention: No social jetlag (no-SJL) group
Number of subjects: 1002
Study 37528295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET) parameters Z-scores
Number of subjects: 909
Study 37528337 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 1589
Study 37528337 — intervention group
Group type: COMPARATOR
Intervention: All other headaches
Number of subjects: 1589
Study 37528337 — intervention group
Group type: COMPARATOR
Intervention: No headaches
Number of subjects: 1589
Study 37528343 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 37528343 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0
Study 37528343 — intervention group
Group type: COMPARATOR
Intervention: Control (unrelated individuals)
Number of subjects: 0
Study 37528391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 803
Study 37528391 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 803
Study 37528405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy including non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 2929
Study 37528405 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2929
Study 37528410 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exposure therapy
Number of subjects: 46
Study 37528410 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation training (Control)
Number of subjects: 46
Study 37528500 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (rescue treatment)
Number of subjects: 0
Study 37528500 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (7.5 mg, 15 mg, 30 mg)
Number of subjects: 0
Study 37528500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37528520 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatments for lupus nephritis
Number of subjects: 0
Study 37528520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of therapy
Number of subjects: 0
Study 37528520 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant disease
Number of subjects: 0
Study 37528520 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific therapies
Number of subjects: 0
Study 37528526 — intervention group
Group type: EXPERIMENTAL
Intervention: A2-CAR T cells (3 million)
Number of subjects: 0
Study 37528526 — intervention group
Group type: EXPERIMENTAL
Intervention: A2-CAR T cells (<3 million) with PBMCs
Number of subjects: 0
Study 37528544 — intervention group
Group type: EXPERIMENTAL
Intervention: Health psychological group intervention
Number of subjects: 10
Study 37528797 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteomic profiling at T1, T2, and T3
Number of subjects: 709
Study 37528797 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of TXNDC5, CTSL, and NPC2 at T2
Number of subjects: 709
Study 37528797 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based prediction model incorporating TXNDC5, CTSL, NPC2, CPB time, and massive blood transfusion
Number of subjects: 709
Study 37528797 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance after 10-fold cross-validation
Number of subjects: 709
Study 37528797 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of the model
Number of subjects: 709
Study 37528797 — intervention group
Group type: EXPERIMENTAL
Intervention: TXNDC5 and CTSL protein levels in lung tissue of LIRI rats
Number of subjects: 709
Study 37529001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'-FL)
Number of subjects: 10
Study 37529001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'-FL) with/without resistant starch (RS)
Number of subjects: 10
Study 37529001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'-FL) with resistant starch (RS)
Number of subjects: 10
Study 37529054 — intervention group
Group type: EXPERIMENTAL
Intervention: Values exercise based on the Disconnected Values Model (DVM)
Number of subjects: 0
Study 37529054 — intervention group
Group type: COMPARATOR
Intervention: Participants without a disconnect
Number of subjects: 0
Study 37529157 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1802 (anti-LAG-3 monoclonal antibody) administered once every 21-day cycle, with doses escalating from 0.3 to 10 mg/kg
Number of subjects: 28
Study 37529158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 23
Study 37529266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal exposed (born 1959-1961)
Number of subjects: 3418
Study 37529266 — intervention group
Group type: EXPERIMENTAL
Intervention: Child exposed (born 1949-1958)
Number of subjects: 3418
Study 37529266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent/adult exposed (born 1931-1948)
Number of subjects: 3418
Study 37529266 — intervention group
Group type: COMPARATOR
Intervention: Unexposed (born 1962-1978)
Number of subjects: 3418
Study 37529919 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib with aromatase inhibitors
Number of subjects: 100
Study 37529919 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib with fulvestrant
Number of subjects: 100
Study 37530453 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone levels measured 2-4 days after MI
Number of subjects: 119
Study 37530456 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (light drinkers)
Number of subjects: 20
Study 37530456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (heavy drinkers)
Number of subjects: 20
Study 37530456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 37530622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort A, B, C)
Number of subjects: 243
Study 37530622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort C)
Number of subjects: 243
Study 37530627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610) with ruxolitinib
Number of subjects: 0
Study 37530627 — intervention group
Group type: COMPARATOR
Intervention: JAKi monotherapy (ruxolitinib, fedratinib, momelotinib)
Number of subjects: 0
Study 37530631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanatinostat 20 mg daily, 4 days per week with valganciclovir 900 mg orally daily for 28-day cycles (phase 2)
Number of subjects: 55
Study 37530660 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal robotic partial nephrectomy (TRPN)
Number of subjects: 2879
Study 37530660 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal robotic partial nephrectomy (RRPN)
Number of subjects: 2879
Study 37530662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN)
Number of subjects: 651
Study 37530662 — intervention group
Group type: COMPARATOR
Intervention: No cytoreductive nephrectomy (no CN)
Number of subjects: 651
Study 37530697 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide
Number of subjects: 0
Study 37530697 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37530822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose VX-548
Number of subjects: 577
Study 37530822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 37530822 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-548 (high-dose)
Number of subjects: 577
Study 37530822 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-548
Number of subjects: 577
Study 37530824 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram or bupropion XL for 52 weeks
Number of subjects: 150
Study 37530824 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 150
Study 37530855 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior implant treatment
Number of subjects: 39
Study 37530892 — intervention group
Group type: EXPERIMENTAL
Intervention: Two flap palatoplasty (TFP)
Number of subjects: 28
Study 37530892 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlow palatoplasty with buccal myomucosal flap (FPBF)
Number of subjects: 28
Study 37530892 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-cleft subjects)
Number of subjects: 28
Study 37530892 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TFP and control group
Number of subjects: 28
Study 37530892 — intervention group
Group type: COMPARATOR
Intervention: Comparison between FPBF and control group
Number of subjects: 28
Study 37530953 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-adapted (LA) 3 ERG
Number of subjects: 214
Study 37530953 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopic negative response (PhNR)
Number of subjects: 214
Study 37531031 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSi surgical simulator training for first-year ORs
Number of subjects: 41
Study 37531031 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSi surgical simulator
Number of subjects: 41
Study 37531083 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (20 mg QD)
Number of subjects: 54
Study 37531083 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (1-2 mg orally, escalated)
Number of subjects: 54